Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 4
1989 3
1992 1
1994 1
1995 1
1996 4
1997 2
1998 3
1999 1
2000 5
2001 1
2002 1
2003 2
2005 1
2006 1
2007 3
2008 3
2009 4
2010 5
2011 4
2012 2
2015 2
2016 3
2017 2
2018 3
2019 3
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Wakita S, et al. Among authors: tajika k. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. Blood Adv. 2022. PMID: 34448807 Free PMC article.
Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, Mori S, Ito S, Koizumi M, Ito Y, Wakita S, Arai K, Kitano T, Kosaka F, Dan K, Inokuchi K. Okabe M, et al. Among authors: tajika k. Leuk Res. 2016 Jan;40:68-76. doi: 10.1016/j.leukres.2015.11.002. Epub 2015 Nov 10. Leuk Res. 2016. PMID: 26614694
Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320.
Arai K, Sakaguchi M, Yui S, Kitano T, Miyata M, Yogosawa M, Nakayama K, Tajika K, Usuki K, Kuroda J, Uoshima N, Kobayashi Y, Uchiyama H, Kubota Y, Kimura S, Mori S, Hirai M, Wakita S, Yamaguchi H. Arai K, et al. Among authors: tajika k. Int J Lab Hematol. 2022 Dec;44(6):1102-1110. doi: 10.1111/ijlh.13938. Epub 2022 Aug 30. Int J Lab Hematol. 2022. PMID: 36039795
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.
Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Sakaguchi M, et al. Among authors: tajika k. Blood Adv. 2018 Oct 23;2(20):2744-2754. doi: 10.1182/bloodadvances.2018020305. Blood Adv. 2018. PMID: 30341082 Free PMC article.
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, Wake A, Tajika K, Sakai R, Kobayashi T, Hua J, Inoue M, Aisa Y, Fujisawa S, Miyazaki K, Irie S, Tanaka E, Higashihara M. Nakazato T, et al. Among authors: tajika k. Ann Hematol. 2021 Nov;100(11):2745-2754. doi: 10.1007/s00277-021-04592-y. Epub 2021 Jul 31. Ann Hematol. 2021. PMID: 34333665 Clinical Trial.
64 results